Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 224

Sort by

Sort Order Select

Journal Articles

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Eytan M. Stein, Leora Boussi, Alice Mims, Justin M. Watts, Gabriel N Mannis, Hongtao Liu, David Sallman, Farhad Ravandi, Gary J. Schiller, Eunice S. Wang, Brian J. Ball, J. Jean Cui, Jihao Zhou, Armin Graber, Zachary Zimmerman, Stephen Anthony Strickland

Blood (2024) 144 (Supplement 1): 5998.

https://doi.org/10.1182/blood-2024-204046

Published: 2024

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, Justin M. Watts, Eunice S. Wang, Jay Yang, Shira N. Dinner, Maria R. Baer, Gail J. Roboz, William B. Donnellan

Blood (2024) 144 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2024-204039

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Marina Konopleva, Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, David A. Rizzieri, Eunice S. Wang, Sumithira Vasu, Todd Rosenblat, Michael Zuurman, Ira Gupta, Andrew A. Lane

Blood (2024) 144 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2024-200230

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study

Blood (2024) 144 (Supplement 1): 6.

https://doi.org/10.1182/blood-2024-202664

Published: 2024

Journal Articles

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Lorenz Oelschläger, Deedra Nicolet, Krzysztof Mrózek, Daniel Schnell, Najla Alotaibi, Christopher J. Walker, Alice Mims, James S. Blachly, Bayard L Powell, Jonathan E Kolitz, Eunice S. Wang, Andrew J. Carroll, Lynn van Rosmalen, Bettina Nadorp, Nathan Salomonis, H. Leighton Grimes, Maarten Fornerod, Ann-Kathrin Eisfeld

Blood (2024) 144 (Supplement 1): 641.

https://doi.org/10.1182/blood-2024-210423

Published: 2024

Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2024) 144 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2024-208504

Published: 2024

Journal Articles

Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy

Sawyer Bawek, Steven Green, Elizabeth A. Griffiths, James E Thompson, Pamela J. Sung, Amanda C. Przespolewski, Eunice S. Wang

Blood (2024) 144 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2024-206258

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2024-199170

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Marlise R. Luskin, Mark Alan Murakami, Julia H. Keating, Yael Flamand, Eric S Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella Louise Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S Wang, Wendy Stock, Daniel J DeAngelo

Blood blood.2024025800.

https://doi.org/10.1182/blood.2024025800

Published: 2024

Includes: Supplemental data

Journal Articles

How I Treat: Secondary Acute Myeloid Leukemia

Steven D Green, Eunice S Wang

Blood blood.2024024011.

https://doi.org/10.1182/blood.2024024011

Published: 2024

Journal Articles

Curing APL in Latin America: more than just ATRA

Eunice S. Wang

Blood (2024) 144 (12): 1237–1238.

https://doi.org/10.1182/blood.2024025429

Published: 2024

Journal Articles

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Blood (2023) 142 (Supplement 1): 4607.

https://doi.org/10.1182/blood-2023-187053

Published: 2023

Journal Articles

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Blood (2023) 142 (Supplement 1): 389.

https://doi.org/10.1182/blood-2023-182376

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Blood (2023) 142 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2023-186340

Published: 2023

NARROW

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

How I Treat: Secondary Acute Myeloid Leukemia

Curing APL in Latin America: more than just ATRA

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only